MorphoSys taps Bavencio lead for US operations; Two top FDA officials move to industry

? Having built out a commercial footprint in the US and led the launch of Bavencio for Merck KGaA, David Trexler is taking up a new role as president of German biotech Morphosys’ US subsidiary. Following a dual listing on the Nasdaq $MOR last year, MorphoSys is plotting a swift rollout for MOR208 once the FDA approves its use in diffuse large B cell lymphoma — now with a guiding hand from Trexler, who’s also worked sales and marketing for Eisai’s US oncology unit.

? Michelle Berrey — the woman who replaced Chimerix CEO Kenneth Moch in 2014 a

Click to view original post